<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Interv Aging</journal-id><journal-id journal-id-type="iso-abbrev">Clin Interv Aging</journal-id><journal-id journal-id-type="publisher-id">Clinical Interventions in Aging</journal-id><journal-title-group><journal-title>Clinical Interventions in Aging</journal-title></journal-title-group><issn pub-type="ppub">1176-9092</issn><issn pub-type="epub">1178-1998</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27932871</article-id><article-id pub-id-type="pmc">5135069</article-id><article-id pub-id-type="doi">10.2147/CIA.S123735</article-id><article-id pub-id-type="publisher-id">cia-11-1751</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety outcomes of fractional flow reserve in guiding clinical therapy of non-ST-segment elevation myocardial infarction compared with angiography alone in elderly Chinese patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhao</given-names></name><xref ref-type="aff" rid="af1-cia-11-1751"/><xref ref-type="author-notes" rid="fn1-cia-11-1751">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="af1-cia-11-1751"/><xref ref-type="author-notes" rid="fn1-cia-11-1751">*</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Jinwen</given-names></name><xref ref-type="aff" rid="af1-cia-11-1751"/><xref ref-type="corresp" rid="c1-cia-11-1751"/></contrib></contrib-group><aff id="af1-cia-11-1751">Department of Cardiology, Chinese People&#x02019;s Liberation Army General Hospital and Hainan Branch, Sanya, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-cia-11-1751">Correspondence: Jinwen Tian, Department of Cardiology, Chinese People&#x02019;s Liberation Army General Hospital and Hainan Branch, Jianglin Street, Haitang Bay, Sanya 572013, People&#x02019;s Republic of China, Tel +86 156 9253 8940, Email <email>tjwsqr.2000@163.com</email></corresp><fn id="fn1-cia-11-1751"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2016</year></pub-date><volume>11</volume><fpage>1751</fpage><lpage>1754</lpage><permissions><copyright-statement>&#x000a9; 2016 Zhang et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Fractional flow reserve (FFR) is an innovative method for evaluating the physiological significance of a coronary stenosis, but its validity is less certain in patients with non-ST-segment elevation myocardial infarction (NSTEMI). It is important to assess whether FFR is effective and safe in patients, especially elderly Chinese patients, with NSTEMI. As the first one in China, the purpose of this study was to establish the efficacy and safety outcomes of FFR in guiding clinical therapy of NSTEMI compared with angiography alone in elderly Chinese patients.</p></sec><sec><title>Patients and methods</title><p>This prospective randomized controlled study included 220 patients with NSTEMI older than 65 years. Patients were assigned in a ratio of 1:1 to the FFR-guided group and the angiography-guided group, and their outcomes were evaluated after 1 year of follow-up.</p></sec><sec><title>Results</title><p>The mean age of the patients was 70&#x000b1;3.6 years, and 69.6% were men. Baseline characteristics of the patients had no differences between the two groups (<italic>P</italic>&#x0003e;0.05 for all). No differences in adverse events, including major adverse cardiovascular event, major adverse cardiovascular and cerebrovascular event, cardiovascular death, nonfatal myocardial infarction, heart failure, stroke, transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding, was observed between the two groups during the follow-up (<italic>P</italic>&#x0003e;0.05 for all). The number of patients receiving medical therapy alone in the FFR-guided group was significantly more than that in the angiography-guided group (<italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>Conclusion</title><p>Compared with angiography-guided standard therapy, FFR reduced the application of percutaneous coronary intervention and obtained similar outcomes, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>elderly Chinese patients</kwd><kwd>fractional flow reserve</kwd><kwd>non-ST-segment elevation myocardial infarction</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide.<xref rid="b1-cia-11-1751" ref-type="bibr">1</xref>,<xref rid="b2-cia-11-1751" ref-type="bibr">2</xref> Angiography is the current standard method applied for clinical therapy of CAD. However, visual assessment of the anatomical severity of a coronary stenosis is subjective and correlates poorly with physiological significance, potentially resulting in inappropriate therapy strategy.<xref rid="b3-cia-11-1751" ref-type="bibr">3</xref> Fractional flow reserve (FFR) is an innovative method for evaluating the physiological significance of a coronary stenosis and is defined as the ratio of maximal blood flow in a stenotic artery to normal maximal flow in the absence of a stenosis. International guidelines have recognized the value of FFR in guiding clinical therapy in patients with stable CAD.<xref rid="b4-cia-11-1751" ref-type="bibr">4</xref>,<xref rid="b5-cia-11-1751" ref-type="bibr">5</xref> However, the validity of FFR is less certain in patients with non-ST-segment elevation myocardial infarction (NSTEMI), and it is an essential issue to assess whether FFR is effective and safe in these patients.<xref rid="b6-cia-11-1751" ref-type="bibr">6</xref> Age and ethnicity-related changes in cardiovascular structure and function have an inevitable effect on FFR, and the role of FFR in clinical therapy of elderly Chinese patients with NSTEMI has not been explored. As the first one in China, the purpose of this study was to establish the efficacy and safety outcomes of FFR in guiding clinical therapy of NSTEMI compared with angiography alone in elderly Chinese patients.</p></sec><sec sec-type="methods|subjects"><title>Patients and methods</title><sec sec-type="subjects"><title>Participants</title><p>This prospective randomized controlled study included 220 patients with NSTEMI older than 65 years of age and was performed in the Department of Cardiology from September 2013 to June 2016. NSTEMI was diagnosed based on acute ischemic symptoms and abnormal myocardial markers but without ST-segment elevation on the electrocardiogram. Exclusion criteria were as follows: 1) ongoing ischemic symptoms after medical therapy; 2) cardiogenic shock or hemodynamic instability; 3) intolerance to antiplatelet drugs; 4) ineligibility for percutaneous coronary intervention (PCI); 5) CAD &#x0003c;30% severity; 6) highly tortuous or calcified coronary arteries; 7) noncoronary cardiosurgery; and 8) life expectancy &#x0003c;1 year. This study was approved by the ethics committee of Chinese People&#x02019;s Liberation Army General Hospital and conducted in line with the Declaration of Helsinki. All patients enrolled in this study provided their written informed consent.</p></sec><sec><title>Processes</title><p>In the clinical medical and invasive therapy, evidence-based guidelines were followed.<xref rid="b7-cia-11-1751" ref-type="bibr">7</xref>&#x02013;<xref rid="b9-cia-11-1751" ref-type="bibr">9</xref> Angiography was performed using standard catheterization room equipment and evaluated visually by an experienced clinician who determined the therapy strategy based on the coronary stenosis severity (stenosis &#x02264; or &#x0003e;70% of reference vessel diameter [50% for left main]). Patients were assigned in a ratio of 1:1 to the FFR-guided group and the angiography-guided group using random digits in a randomized block design. After coronary dilation caused by intravenous infusion of adenosine (140 &#x000b5;g/kg/min), patients in the FFR-guided group had FFR measured using a pressure-sensitive coronary guidewire (St Jude Medical, Inc., St Paul, MN, USA). A cutoff point of 0.80 was the standard selecting PCI (&#x02264;0.80) or medical therapy alone (&#x0003e;0.80).</p></sec><sec><title>Outcomes</title><p>The following outcomes were evaluated after 1 year of follow-up: 1) adverse events, including major adverse cardiovascular event defined as cardiovascular death, nonfatal myocardial infarction, or unplanned hospitalization for heart failure, major adverse cardiovascular and cerebrovascular event defined as cardiovascular death, nonfatal myocardial infarction, unplanned hospitalization for stroke, or transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding, and 2) therapy strategies (PCI or medical therapy alone).</p></sec><sec><title>Statistics</title><p>Continuous data were presented as mean (standard deviation) or median (interquartile range), and categorical data were presented as number (percentage). Continuous variables between the two groups were compared using Student&#x02019;s <italic>t</italic>-test or Mann&#x02013;Whitney <italic>U</italic> test, and categorical variables between the two groups were compared using Chi-square test. All analyses were two tailed at the 5% significance level using Statistical Package for the Social Sciences Version 17.0 software (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The mean age of all patients were 70&#x000b1;3.6 years, and 69.6% were men. As shown in <xref ref-type="table" rid="t1-cia-11-1751">Table 1</xref>, baseline characteristics of patients had no differences between the two groups (<italic>P</italic>&#x0003e;0.05 for all). As shown in <xref ref-type="table" rid="t2-cia-11-1751">Table 2</xref>, no differences in adverse events including major adverse cardiovascular event, major adverse cardiovascular and cerebrovascular event, cardiovascular death, nonfatal myocardial infarction, heart failure, stroke, transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding were observed between the two groups during the follow-up (<italic>P</italic>&#x0003e;0.05 for all). Based on angiography alone, there were nine patients receiving medical therapy alone in the FFR-guided group and no difference with patients in the angiography-guided group (<italic>P</italic>&#x0003e;0.05). Based on FFR, the other six patients (5.5%) received medical therapy alone in the FFR-guided group. Patients receiving medical therapy alone in the FFR-guided group (15 patients) were significantly more than those in the angiography-guided group (six patients; <italic>P</italic>&#x0003c;0.05).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The current standard method applied for clinical therapy of NSTEMI is angiography with visual interpretation of anatomical severity of a coronary stenosis. FFR is an innovative method evaluating the physiological significance of a coronary artery stenosis and is able to determine the therapy strategies. FFR is gradually applied in patients with stable CAD due to the approval of international guidelines. However, in patients, especially elderly Chinese patients, with NSTEMI, FFR-guided therapy is not the standard method, mainly because of lacking evidence. This study showed that FFR-guided therapy reduced the application of PCI and obtained similar outcomes compared with angiography alone, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients.</p><p>FFR had important implications in advancing clinical therapy of stable CAD.<xref rid="b10-cia-11-1751" ref-type="bibr">10</xref> Studies such as DEFER and FAME have confirmed the benefits of FFR in stable CAD to more precisely guide the clinical therapy.<xref rid="b11-cia-11-1751" ref-type="bibr">11</xref>,<xref rid="b12-cia-11-1751" ref-type="bibr">12</xref> The validity of FFR is less clear in patients with acute coronary syndrome (ACS) due to the likelihood that coronary response to vasodilators may be decreased due to coronary obstruction. Coronary lesion of patients with ST-segment elevation myocardial infarction may limit the dilatation of coronary and the validity of FFR.<xref rid="b13-cia-11-1751" ref-type="bibr">13</xref> However, FFR may be valuable in patients with NSTEMI because its lesion is typically nonocclusive thrombotic plaque rupture and subendocardial infarction with transient coronary dysfunction and preserved blood flow.<xref rid="b14-cia-11-1751" ref-type="bibr">14</xref> Coronary reserve has been found to be similar in patients with stable angina and NSTEMI, which is consistent with preserved dilation ability in patients with stable ACS.<xref rid="b14-cia-11-1751" ref-type="bibr">14</xref> A post hoc analysis of patients with stable ACS in the FAME study has suggested the validity of FFR.<xref rid="b15-cia-11-1751" ref-type="bibr">15</xref> The FAMOUS-NSTEMI study has reported on the efficacy and safety of FFR-guided therapy in patients with NSTEMI.<xref rid="b16-cia-11-1751" ref-type="bibr">16</xref></p><p>Uncertainty for FFR application was specifically addressed in elderly Chinese patients and similarly caused by lacking evidence. In a post hoc analysis of patients in the FAME study, Lim et al<xref rid="b17-cia-11-1751" ref-type="bibr">17</xref> have highlighted that FFR-guided therapy was similarly beneficial irrespective of age. Results of this study also illustrated that FFR was feasible because it not only determined the decreased application of PCI but was also not associated with worse outcomes in elderly Chinese patients with NSTEMI.</p><p>This study had several limitations. The sample size is relatively small, and the follow-up duration is relatively short in this study, so it is necessary to conduct large-scale studies with long follow-up periods to confirm the results obtained from this study.</p></sec><sec><title>Conclusion</title><p>This study confirmed that, compared with angiography-guided standard therapy, FFR reduced the application of PCI and obtained similar outcomes, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cia-11-1751"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Roger</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics &#x02013; 2014 update: a report from the American Heart Association</article-title><source>Circulation</source><year>2014</year><volume>129</volume><fpage>e28</fpage><lpage>e292</lpage><pub-id pub-id-type="pmid">24352519</pub-id></element-citation></ref><ref id="b2-cia-11-1751"><label>2</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organisation [webpage on the Internet]</collab></person-group><source>Cardiovascular disease</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cardiovascular_diseases/en/">http://www.who.int/cardiovascular_diseases/en/</ext-link></comment><date-in-citation>Accessed March 15, 2015</date-in-citation></element-citation></ref><ref id="b3-cia-11-1751"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Corcoran</surname><given-names>D</given-names></name><name><surname>Hennigan</surname><given-names>B</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Layland</surname><given-names>J</given-names></name><name><surname>Oldroyd</surname><given-names>KG</given-names></name></person-group><article-title>Fractional flow, reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>45</issue><fpage>3155</fpage><lpage>3164</lpage><pub-id pub-id-type="pmid">26038588</pub-id></element-citation></ref><ref id="b4-cia-11-1751"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Achenbach</surname><given-names>S</given-names></name><etal/></person-group><article-title>ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>2949</fpage><lpage>3003</lpage><pub-id pub-id-type="pmid">23996286</pub-id></element-citation></ref><ref id="b5-cia-11-1751"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><etal/></person-group><article-title>ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>2541</fpage><lpage>2619</lpage><pub-id pub-id-type="pmid">25173339</pub-id></element-citation></ref><ref id="b6-cia-11-1751"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuculi</surname><given-names>F</given-names></name><name><surname>De Maria</surname><given-names>GL</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><issue>18</issue><fpage>1894</fpage><lpage>1904</lpage><pub-id pub-id-type="pmid">25444143</pub-id></element-citation></ref><ref id="b7-cia-11-1751"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><etal/></person-group><article-title>ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>2999</fpage><lpage>3054</lpage><pub-id pub-id-type="pmid">21873419</pub-id></element-citation></ref><ref id="b8-cia-11-1751"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><etal/></person-group><article-title>ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>e215</fpage><lpage>e367</lpage><pub-id pub-id-type="pmid">21545940</pub-id></element-citation></ref><ref id="b9-cia-11-1751"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Danchin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Guidelines on myocardial revascularization</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>2501</fpage><lpage>2555</lpage><pub-id pub-id-type="pmid">20802248</pub-id></element-citation></ref><ref id="b10-cia-11-1751"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>de Bruyne</surname><given-names>B</given-names></name><name><surname>Pijls</surname><given-names>NH</given-names></name><etal/><collab>FAME Study Investigators</collab></person-group><article-title>Fractional flow reserve versus angiography for guiding percutaneous coronary intervention</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>3</issue><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">19144937</pub-id></element-citation></ref><ref id="b11-cia-11-1751"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijls</surname><given-names>NH</given-names></name><name><surname>van Schaardenburgh</surname><given-names>P</given-names></name><name><surname>Manoharan</surname><given-names>G</given-names></name><etal/></person-group><article-title>Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><issue>21</issue><fpage>2105</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">17531660</pub-id></element-citation></ref><ref id="b12-cia-11-1751"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name><name><surname>De Bruyne</surname><given-names>B</given-names></name><etal/></person-group><article-title>Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>25</issue><fpage>2816</fpage><lpage>2821</lpage><pub-id pub-id-type="pmid">20579537</pub-id></element-citation></ref><ref id="b13-cia-11-1751"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uren</surname><given-names>NG</given-names></name><name><surname>Crake</surname><given-names>T</given-names></name><name><surname>Lefroy</surname><given-names>DC</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>GJ</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><issue>4</issue><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">7832835</pub-id></element-citation></ref><ref id="b14-cia-11-1751"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layland</surname><given-names>J</given-names></name><name><surname>Carrick</surname><given-names>D</given-names></name><name><surname>McEntegart</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction</article-title><source>Circ Cardiovasc Interv</source><year>2013</year><volume>6</volume><issue>3</issue><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">23756697</pub-id></element-citation></ref><ref id="b15-cia-11-1751"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sels</surname><given-names>JW</given-names></name><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>Siebert</surname><given-names>U</given-names></name><etal/></person-group><article-title>Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (fractional flow reserve versus angiography for multivessel evaluation) study</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><issue>11</issue><fpage>1183</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">22115657</pub-id></element-citation></ref><ref id="b16-cia-11-1751"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layland</surname><given-names>J</given-names></name><name><surname>Oldroyd</surname><given-names>KG</given-names></name><name><surname>Curzen</surname><given-names>N</given-names></name><etal/><collab>FAMOUS&#x02013;NSTEMI investigators</collab></person-group><article-title>Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>2</issue><fpage>100</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">25179764</pub-id></element-citation></ref><ref id="b17-cia-11-1751"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>HS</given-names></name><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>De Bruyne</surname><given-names>B</given-names></name><etal/></person-group><article-title>The impact of age on fractional flow reserve-guided percutaneous coronary intervention: a FAME (fractional flow reserve versus angiography for multivessel evaluation) trial substudy</article-title><source>Int J Cardiol</source><year>2014</year><volume>177</volume><issue>1</issue><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25499342</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-cia-11-1751" position="float"><label>Table 1</label><caption><p>Baseline characteristics of patients in clinical therapy guided by FFR or angiography alone</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">FFR-guided group<break/>(n=110)</th><th valign="top" align="left" rowspan="1" colspan="1">Angiography-guided group<break/>(n=110)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td valign="top" align="left" rowspan="1" colspan="1">70&#x000b1;3.7</td><td valign="top" align="left" rowspan="1" colspan="1">70&#x000b1;3.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.267</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Men, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">75 (68.2)</td><td valign="top" align="left" rowspan="1" colspan="1">78 (70.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.660</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.908</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Current</td><td valign="top" align="left" rowspan="1" colspan="1">29 (26.4)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (28.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Former</td><td valign="top" align="left" rowspan="1" colspan="1">41 (37.3)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (34.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Never</td><td valign="top" align="left" rowspan="1" colspan="1">40 (36.4)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (37.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous MI, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (21.8)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (20.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.869</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Heart failure, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">81 (73.6)</td><td valign="top" align="left" rowspan="1" colspan="1">83 (75.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.757</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (36.4)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (32.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.571</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">90 (81.8)</td><td valign="top" align="left" rowspan="1" colspan="1">93 (84.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.589</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Peak troponin levels, n (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;&#x000d7;5 upper limit of normal</td><td valign="top" align="left" rowspan="1" colspan="1">87 (79.1)</td><td valign="top" align="left" rowspan="1" colspan="1">82 (74.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.424</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;&#x000d7;10 upper limit of normal</td><td valign="top" align="left" rowspan="1" colspan="1">69 (62.7)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (58.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.491</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Procedural characteristics, n (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Radial artery access</td><td valign="top" align="left" rowspan="1" colspan="1">95 (86.4)</td><td valign="top" align="left" rowspan="1" colspan="1">98 (89.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.538</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Aspirin</td><td valign="top" align="left" rowspan="1" colspan="1">110 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1">110 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Clopidogrel</td><td valign="top" align="left" rowspan="1" colspan="1">89 (80.9)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (78.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.616</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">21 (19.1)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (21.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.616</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Statin</td><td valign="top" align="left" rowspan="1" colspan="1">103 (93.6)</td><td valign="top" align="left" rowspan="1" colspan="1">105 (95.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.553</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Beta-blocker</td><td valign="top" align="left" rowspan="1" colspan="1">74 (67.3)</td><td valign="top" align="left" rowspan="1" colspan="1">73 (66.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.886</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CCB</td><td valign="top" align="left" rowspan="1" colspan="1">45 (40.9)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (44.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.586</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nitrates</td><td valign="top" align="left" rowspan="1" colspan="1">98 (89.1)</td><td valign="top" align="left" rowspan="1" colspan="1">96 (87.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.676</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;LMWH</td><td valign="top" align="left" rowspan="1" colspan="1">101 (91.8)</td><td valign="top" align="left" rowspan="1" colspan="1">102 (92.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.801</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cia-11-1751"><p><bold>Abbreviations:</bold> CCB, calcium channel blocker; FFR, fractional flow reserve; LMWH, low molecular weight heparin; MI, myocardial infarction; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cia-11-1751" position="float"><label>Table 2</label><caption><p>Outcomes of patients in clinical therapy guided by FFR or angiography alone</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Outcomes</th><th valign="top" align="left" rowspan="1" colspan="1">FFR-guided groupM<break/>(n=110)</th><th valign="top" align="left" rowspan="1" colspan="1">Angiography-guided group<break/>(n=110)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" rowspan="1">Adverse events</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MACE</td><td valign="top" align="left" rowspan="1" colspan="1">9 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.639</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MACCE</td><td valign="top" align="left" rowspan="1" colspan="1">10 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (11.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.509</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Cardiovascular death</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.734</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nonfatal MI</td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.553</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Heart failure</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.734</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Stroke</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;TIA</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;All-cause mortality</td><td valign="top" align="left" rowspan="1" colspan="1">9 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.639</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Contrast nephropathy</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.477</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Major bleeding</td><td valign="top" align="left" rowspan="1" colspan="1">2 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Therapy strategies</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.039</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Medical therapy</td><td valign="top" align="left" rowspan="1" colspan="1">15 (13.6)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PCI</td><td valign="top" align="left" rowspan="1" colspan="1">95 (86.4)</td><td valign="top" align="left" rowspan="1" colspan="1">104 (94.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn2-cia-11-1751"><p><bold>Notes:</bold> Data presented as n (%). MACE is defined as cardiovascular death, nonfatal MI, or unplanned hospitalization for heart failure; MACCE is defined as cardiovascular death, nonfatal MI, unplanned hospitalization for stroke, or TIA.</p></fn><fn id="tfn3-cia-11-1751"><p><bold>Abbreviations:</bold> FFR, fractional flow reserve; MACE, major adverse cardiac event; MACCE, major adverse cardiac and cerebral event; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></floats-group></article>